PR Newswire BiotechOriginal article
XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation
Phase 1Positive
AI Analysis
Summary
XtalPi nominated its first siRNA preclinical candidate for IgA Nephropathy treatment, demonstrating subnanomolar silencing potency with IC50 values significantly superior to clinical-stage reference molecules and sustained target suppression in non-human primate studies.
Outcome Details
Preclinical candidate nominated; subnanomolar silencing potency demonstrated with IC50 tens of times lower than clinical-stage reference molecules; single dose in non-human primates maintained robust target-protein suppression
Importance:5/10
Sentiment:
0.70
siRNAIgA Nephropathypreclinicaldrug developmentrare disease
Read the original article
Published by PR Newswire Biotech on October 15, 2026 3:38 PM